Fam Cancer
Genetics Centre, Guy's & St Thomas' Hospital NHS Trust, London, SE1 9RT, UK.
Published: September 2007
BRCA1 exon deletions and duplications have been reported in a number of studies, and in order to design an effective mutation screening strategy in a diagnostic setting it is import to determine the frequency of this type of mutation in breast and ovarian cancer patients. We have designed and applied quantitative fluorescent PCR (QF-PCR) assays to screen for BRCA1 exon rearrangements in breast cancer patients both with and without a family history. A panel of 182 familial patients was screened, and an exon 3-7 deletion mutation was detected in a patient with a family history of breast and ovarian cancer. Additionally, we detected a duplication of exons 18-19 in an early onset sporadic breast cancer patient from a panel of 100 patients tested. These data indicate that in the absence of any founder mutations, screening for BRCA1 exon rearrangements does not significantly increase the overall BRCA1 mutation detection rate in patients referred to a genetics clinic because of either a family history and/or an early onset of disease.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1007/s10689-006-0001-0 | DOI Listing |
J Med Life
January 2025
Department of Chemical-Biological Sciences, Autonomous University of Ciudad Juarez, Ciudad Juarez, Chihuahua, Mexico.
Breast and ovarian cancers are significant global health challenges, with inherited variations in breast cancer gene 1 () and breast cancer gene 2 () substantially increasing the risk, aggressiveness, and early onset of these diseases. This work aimed to examine pathogenic variants (PVs) in and databases that include Mexican populations. A systematic review of literature and data mining spanning from 2002 to 2023 was conducted.
View Article and Find Full Text PDFPurpose: Variants of uncertain significance (VUS) are considered one of the most significant impediments to the translation of genetic test results into precise clinical recommendations. The 2015 American College of Medical Genetics and Genomics/Association for Molecular Pathology (ACMG/AMP) classification guidelines established a general framework for the assessment and classification of genetic variants; yet, gene-specific specifications are needed to enable better variant classification to reduce the number of VUS. The process of gene-specific adaptations of the ACMG/AMP codes is led and accompanied by ClinGen and implemented by Variant Curation Expert Panels (VCEP).
View Article and Find Full Text PDFFront Oncol
February 2025
Laboratory of Medical Genetics, Centro Diagnostico Italiano, Milan, Italy.
Pathogenic/likely pathogenic germline variants in the and genes are associated with an increased risk of developing cancer, particularly breast and/or ovarian tumors. The identification and correct classification of these variants is crucial to find individuals with an increased risk of cancer and to support physicians in their clinical and therapeutic decisions. In addition, the status of and variants is important for appropriate management of patients' family members.
View Article and Find Full Text PDFClin Transl Oncol
January 2025
Inflammation and Cancer Biology Laboratory, Department of Molecular Biology and Biotechnology, Tezpur University, Tezpur, Assam, 784028, India.
Globally, breast and ovarian cancers are major health concerns in women and account for significantly high cancer-related mortality rates. Dysregulations and mutations in genes like TP53, BRCA1/2, KRAS and PTEN increase susceptibility towards cancer. Here, we discuss the impact of mutations in the key regulatory gene, TP53 and polymorphisms in its negative regulator MDM2 which are reported to accelerate cancer progression.
View Article and Find Full Text PDFClin Transl Med
January 2025
Unit of Molecular Biology, Georges-François Leclerc Cancer center, UNICANCER, Dijon, France.
Background: Molecular diagnosis has become highly significant for patient management in oncology.
Methods: Here, 30 well-characterized clinical germline samples were studied with adaptive sampling to enrich the full sequence of 152 cancer predisposition genes. Sequencing was performed on Oxford Nanopore (ONT) R10.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!
© LitMetric 2025. All rights reserved.